Skip to main content

Table 1 Baseline characteristics of the unmatched and propensity score matched cohorts

From: Mid-term outcomes of Sapien 3 versus Perimount Magna Ease for treatment of severe aortic stenosis

  Unmatched cohort Propensity score matched cohort
Clinical variables Sapien 3
(N = 689)
Perimount Magna Ease
(N = 1311)
Standardized difference p-value Sapien 3
(N = 308)
Perimount Magna Ease
(N = 308)
Standardized difference p-value
Age, yrs 81.3 ± 6.4 74.0 ± 6.9 1.1 < 0.0001 78.8 ± 6.9 79.0 ± 5.3 −0.03 0.697
Female 365 (53.0) 556 (42.4) 0.21 < 0.0001 160 (51.9) 165 (53.6) −0.03 0.674
BMI, kg/m2 27.4 ± 4.9 28.0 ± 4.8 −0.12 0.012 28.1 ± 5.2 28.0 ± 5.0 0.02 0.848
Diabetes mellitus 207 (30.0) 353 (26.9) 0.07 0.140 93 (30.2) 87 (28.2) 0.04 0.578
Atrial fibrillation 293 (42.5) 255 (19.5) 0.52 < 0.0001 102 (33.1) 99 (32.1) 0.02 0.782
Extracardiac arteriopathy 117 (17.0) 137 (10.5) 0.19 < 0.0001 49 (15.9) 41 (13.3) 0.07 0.383
Chronic lung disease 149 (21.6) 172 (13.1) 0.23 < 0.0001 65 (21.1) 62 (20.1) 0.02 0.761
Hemoglobin, g/l 125.7 ± 15.2 133.6 ± 15.1 −0.53 < 0.0001 128.7 ± 15.2 127.8 ± 15.3 0.06 0.421
eGFR, ml/m2/min 62.0 ± 18.5 72.6 ± 16.7 −0.60 < 0.0001 65.6 ± 18.1 66.4 ± 16.1 −0.05 0.550
History of stroke 70 (10.2) 70 (5.3) 0.18 0.0001 27 (8.8) 29 (9.4) −0.02 0.782
Prior pacemaker 65 (9.4) 50 (3.8) 0.23 < 0.0001 20 (6.5) 19 (6.2) 0.01 0.862
Previous cardiac surgery 110 (16.0) 24 (1.8) 0.51 < 0.0001 17 (5.5) 18 (5.8) −0.01 0.847
Prior PCI 140 (20.3) 130 (9.9) 0.29 < 0.0001 47 (15.3) 40 (13.0) 0.07 0.370
Coronary artery disease 181 (26.3) 563 (42.9) −0.36 < 0.0001 102 (33.1) 97 (31.5) 0.04 0.665
No. of diseased vessels 0.36 ± 0.7 0.78 ± 1.1 −0.48 < 0.0001 0.47 ± 0.8 0.46 ± 0.8 0.02 0.836
Recent MI 17 (2.5) 72 (5.5) −0.16 0.0018 9 (2.9) 9 (2.9) 0.00 1.000
NYHA class IV 82 (11.9) 94 (7.2) 0.16 0.0004 31 (10.1) 34 (11.0) −0.03 0.696
AHF 75 (10.9) 101 (7.7) 0.11 0.017 33 (10.7) 33 (10.7) 0.00 1.000
Urgent procedure 55 (8.0) 148 (11.3) −0.11 0.020 28 (9.1) 33 (10.7) −0.05 0.508
Ejection fraction    0.26 < 0.0001    0.08 0.699
  > 50% 499 (72.4) 1069 (81.5)    230 (74.7) 239 (77.6)   
 31–50% 158 (22.9) 220 (16.8)    68 (22.1) 60 (19.5)   
 21–30% 31 (4.5) 22 (1.7)    10 (3.2) 9 (2.9)   
Sys. pulmonary pressure    0.74 < 0.0001    0.09 < 0.0001
 31–55 mmHg 245 (35.6) 524 (40.0)    131 (42.5) 121 (39.3)   
  > 55 mmHg 75 (10.9) 92 (7.0)    34 (11.0) 39 (12.7)   
Mitral valve regurgitation    0.56 < 0.0001    0.06 0.652
 Mild 255 (37.0) 278 (21.2)    116 (37.7) 107 (34.7)   
 Moderate 80 (11.6) 39 (3.0)    23 (7.5) 21 (6.8)   
Concomitant coronary revascularization 29 (4.2) 511 (39.0) −0.78 < 0.0001 14 (4.5) 84 (27.3) −0.62 < 0.0001
EuroSCORE II, % 6.5 ± 7.1 3.4 ± 4.2 0.52 < 0.0001 5.0 ± 5.2 4.9 ± 5.9 0.02 0.752
STS-PROM, % 4.3 ± 2.9 2.6 ± 2.1 0.67 < 0.0001 3.5 ± 2.2 3.5 ± 2.8 0.01 0.918
  1. Categorical values are reported as counts and percentages. Continuous variables are reported as mean and standard deviation. AHF acute heart failure (within 60 days before procedure or critical preoperative state), BMI body mass index, eGFR estimated glomerular filtration rate, EuroSCORE European System for Cardiac Operative Risk Evaluation, MI myocardial infarction within 90 days before procedure, NYHA New York Heart Association, PCI percutaneous coronary intervention, STS-PROM Society of Thoracic Surgeons Predicted Risk of Mortality